One-off anti-TNF treatment due for review

The National Institute of Clinical Excellence (Nice) is to review its guidelines on the use of new drugs for treating rheumatoid arthritis. Presently, NHS patients are allowed just one anti-TNF (tumour necrosis factor alpha) drug, a treatment costing a minimum of £100 a week that can slow the progress of the condition and help reduce joint pain, swelling, mobility and fatigue. Ailsa Bostworth, chief executive of the National Rheumatoid Arthritis Society, said: "We are delighted that Nice has listened to patients and clinicians and agreed to re-look at the evidence for the sequential use...